These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 7604791)
21. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Appel S; Rüfenacht T; Kalafsky G; Tetzloff W; Kallay Z; Hitzenberger G; Kutz K Am J Cardiol; 1995 Jul; 76(2):29A-32A. PubMed ID: 7604792 [TBL] [Abstract][Full Text] [Related]
22. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. Raiteri M; Arnaboldi L; McGeady P; Gelb MH; Verri D; Tagliabue C; Quarato P; Ferraboschi P; Santaniello E; Paoletti R; Fumagalli R; Corsini A J Pharmacol Exp Ther; 1997 Jun; 281(3):1144-53. PubMed ID: 9190847 [TBL] [Abstract][Full Text] [Related]
23. Effects of fluvastatin and its major metabolites on low-density lipoprotein oxidation and cholesterol esterification in macrophages. Tanaka K; Yasuhara M; Suzumura K; Narita H; Suzuki T Jpn J Pharmacol; 2001 Jul; 86(3):289-96. PubMed ID: 11488428 [TBL] [Abstract][Full Text] [Related]
28. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. Mitani H; Egashira K; Kimura M Pharmacol Res; 2003 Nov; 48(5):417-27. PubMed ID: 12967585 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Flint OP; Masters BA; Gregg RE; Durham SK Toxicol Appl Pharmacol; 1997 Jul; 145(1):91-8. PubMed ID: 9221828 [TBL] [Abstract][Full Text] [Related]
30. Mevalonate is essential for growth of porcine and human vascular smooth muscle cells in vitro. Rogler G; Lackner KJ; Schmitz G Basic Res Cardiol; 1995; 90(6):443-50. PubMed ID: 8773189 [TBL] [Abstract][Full Text] [Related]
31. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells. Ito T; Ikeda U; Shimpo M; Ohki R; Takahashi M; Yamamoto K; Shimada K Cardiovasc Drugs Ther; 2002 Mar; 16(2):121-6. PubMed ID: 12090904 [TBL] [Abstract][Full Text] [Related]
32. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. Tesfamariam B; Frohlich BH; Gregg RE J Cardiovasc Pharmacol; 1999 Jul; 34(1):95-101. PubMed ID: 10413074 [TBL] [Abstract][Full Text] [Related]
33. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin. Del Puppo M; Rauli S; Galli Kienle M Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435 [TBL] [Abstract][Full Text] [Related]
34. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes. Corsini A; Arnaboldi L; Raiteri M; Quarato P; Faggiotto A; Paoletti R; Fumagalli R Pharmacol Res; 1996 Jan; 33(1):55-61. PubMed ID: 8817647 [TBL] [Abstract][Full Text] [Related]
35. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Corsini A; Raiteri M; Soma M; Fumagalli R; Paoletti R Pharmacol Res; 1991 Feb; 23(2):173-80. PubMed ID: 1905808 [TBL] [Abstract][Full Text] [Related]
36. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Bellosta S; Via D; Canavesi M; Pfister P; Fumagalli R; Paoletti R; Bernini F Arterioscler Thromb Vasc Biol; 1998 Nov; 18(11):1671-8. PubMed ID: 9812903 [TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Bandoh T; Mitani H; Niihashi M; Kusumi Y; Ishikawa J; Kimura M; Totsuka T; Sakurai I; Hayashi S Eur J Pharmacol; 1996 Nov; 315(1):37-42. PubMed ID: 8960862 [TBL] [Abstract][Full Text] [Related]
38. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. Turner NA; Midgley L; O'Regan DJ; Porter KE J Cardiovasc Pharmacol; 2007 Oct; 50(4):458-61. PubMed ID: 18049315 [TBL] [Abstract][Full Text] [Related]
39. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
40. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Inoue M; Nakamura H Gastroenterology; 2002 Feb; 122(2):308-17. PubMed ID: 11832446 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]